<DOC>
	<DOCNO>NCT02603614</DOCNO>
	<brief_summary>CNDP-578-02 randomize , double-blind , placebo-controlled , dose-escalation , crossover design trial . Eight evaluable subject ( n=8 ) chronic stable heart failure moderate renal impairment randomize ( 1:1 ) receive cenderitide placebo . Enrolled subject begin Infusion Period A receive 7 day continuous , subcutaneous , dose-escalating infusion cenderitide placebo via Insulet Drug Delivery System . Enrolled subject cross Infusion Period B receive 7 day continuous , subcutaneous , dose-escalating infusion cenderitide placebo .</brief_summary>
	<brief_title>Safety Study Cenderitide Chronic Stable Heart Failure With Moderate Renal Impairment</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Willing able provide write informed consent review design risk study prior complete studyrelated procedure Willing able understand comply study procedures requirement , include inpatient stay Current historical New York Heart Association ( NYHA ) functional class ≥ II Glomerular Filtration Rate ( GFR ) ≥ 30 ≤ 60 mL/min time screen Systolic blood pressure 120160 mmHg time screen Stable compliant treatment oral medication least 4 week prior screen Body Mass Index ( BMI ) ≥18 ≤45 kg/m2 time screen Women child bear potential ( WOCBP ) males must agree use least two form contraception , one include barrier method ( male condom ) male partner , study participation continue least 90 day conclusion final infusion rate . In addition , sperm donation male subject permit subject 's participation research study least 90 day conclusion final infusion rate . This criterion may waive male subject undergone vasectomy least 6 month prior screen Willing able abstain drug , alcohol , tobacco study participation Hypersensitivity allergy natriuretic peptide Acute decompensated heart failure ( ADHF ) within 30 day prior randomization Clinical diagnosis acute coronary syndrome ( ACS ) within 30 day prior randomization Symptomatic postural hypotension Concomitant medication aldosterone blocker ( e.g. , eplerenone spironolactone ) within 30 day prior randomization Potassium ≥ 5.0 mmol/L Evidence uncorrected volume sodium ≤ 130 mmol/L within 24 hour prior randomization Clinically significant aortic mitral valve stenosis Acute myocarditis hypertrophic obstructive , restrictive , constrictive cardiomyopathy ( include restrictive mitral filling pattern ) Significant pulmonary disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Chronic Heart Failure</keyword>
	<keyword>Renal Insufficiency</keyword>
	<keyword>Natriuretic Peptides</keyword>
	<keyword>Cenderitide</keyword>
</DOC>